atg-101
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2021 (NCT04986865)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05490043 | Phase 1 | Jan 30, 2022 | Antengene Corporation, Innovaderm |
| NCT04986865 | Phase 1 | Oct 1, 2021 | Antengene Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antengene Corporation | For profit | 2 | 2 | 1 | 2021 |
| Innovaderm | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1